Corning Life Sciences Introduces Corning® HepatoCells

We use cookies to ensure the best experience on our website.
View Cookie Policy
Accept Cookie Policy
Change My Settings
Required for the site to function.
Augment your site experience.
Lets Corning work with partners to enable social features and marketing messages.
Corning Life Sciences Introduces Corning® HepatoCells

Corning® HepatoCells

Corning® HepatoCells

News Releases
Corporate Communications
Corning Life Sciences Introduces Corning® HepatoCells
Corning Life Sciences Introduces Corning® HepatoCells
Corning, N.Y. | Corning Life Sciences | July 30, 2015
Single-use, highly consistent alternative to primary human hepatocytes

 Corning Incorporated (NYSE: GLW) today announced the launch of Corning HepatoCells, a robust, consistent and convenient alternative to primary human hepatocytes for ADME/Tox research.

HepatoCells are single-use, cryopreserved cells derived from primary human hepatocytes using Corning proprietary immortalization technology. These cells exhibit the distinct morphology of mature primary hepatocytes and maintain key functional characteristics, while providing the convenience of a renewable resource.

Primary human hepatocytes, the current standard for researching drug metabolism, disposition, and hepatic toxicity, have many well-known limitations, including high cost, finite lot supplies, and inter-individual variability.  Corning HepatoCells provide researchers a solution with a reliable hepatocyte source and improved functionality relative to comparable alternatives.

The benefits of Corning HepatoCells, compared with primary hepatocytes, are:

  • Robust induction response for major Cytochrome P450 (CYP) enzymes
  • Consistent lot-to-lot performance
  • Convenience of use, with only a single medium required for the entire culturing and assay process
  • A high post thaw viability (> 80 percent), as well as recovery and purity

Corning HepatoCells, available and optimized with a companion Corning medium, is qualified for many applications, including Cytochrome P450 induction and cytotoxicity, making it an ideal non-primary hepatic model to study drug-drug interactions (DDI) and liver toxicity of xenobiotics for drug discovery and development.  

 “We are very excited about the commercial launch of HepatoCells,” said Charles Crespi, director of new product realization, Corning Life Sciences. “This product provides scientists with a virtually unlimited supply of primary hepatocyte-like cells and enables early characterization of ADME and DDI properties for drug developers. It will be a nice complement to our current primary hepatocyte product portfolio.”

Corning HepatoCells will be available in North America starting July 31. The product will be available globally later in 2015.

Corning Life Sciences continues to bring new and innovative laboratory technologies to researchers worldwide and help customers succeed by providing novel, high-quality products and services in cell culture, bioprocessing, drug discovery and development, genomics, and microbiology. 

To learn more about Corning’s Life Sciences products, please contact a customer service representative at 1-800-492-1110, toll free in the United States; (+1) 1-978-442-2200 internationally; or visit

Forward-Looking and Cautionary Statements

This press release contains “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995), which are based on current expectations and assumptions about Corning’s financial results and business operations, that involve substantial risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include: the effect of global political, economic and business conditions; conditions in the financial and credit markets; currency fluctuations; tax rates; product demand and industry capacity; competition; reliance on a concentrated customer base; manufacturing efficiencies; cost reductions; availability of critical components and materials; new product commercialization; pricing fluctuations and changes in the mix of sales between premium and non-premium products; new plant start-up or restructuring costs; possible disruption in commercial activities due to terrorist activity, armed conflict, political or financial instability, natural disasters, adverse weather conditions, or major health concerns; adequacy of insurance; equity company activities; acquisition and divestiture activities; the level of excess or obsolete inventory; the rate of technology change; the ability to enforce patents; product and components performance issues; retention of key personnel; stock price fluctuations; and adverse litigation or regulatory developments. These and other risk factors are detailed in Corning’s filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the day that they are made, and Corning undertakes no obligation to update them in light of new information or future events.

About Corning Incorporated

Corning ( is one of the world’s leading innovators in materials science. For more than 160 years, Corning has applied its unparalleled expertise in specialty glass, ceramics, and optical physics to develop products that have created new industries and transformed people’s lives. Corning succeeds through sustained investment in R&D, a unique combination of material and process innovation, and close collaboration with customers to solve tough technology challenges. Corning’s businesses and markets are constantly evolving. Today, Corning’s products enable diverse industries such as consumer electronics, telecommunications, transportation, and life sciences. They include damage-resistant cover glass for smartphones and tablets; precision glass for advanced displays; optical fiber, wireless technologies, and connectivity solutions for high-speed communications networks; trusted products that accelerate drug discovery and manufacturing; and emissions-control products for cars, trucks, and off-road vehicles.